Advertisement
Canada markets closed

  • S&P/TSX

    21,788.48
    -60.11 (-0.28%)
     

  • S&P 500

    5,469.30
    +21.43 (+0.39%)
     

  • DOW

    39,112.16
    -299.05 (-0.76%)
     

  • CAD/USD

    0.7324
    +0.0001 (+0.01%)
     

  • CRUDE OIL

    80.89
    +0.06 (+0.07%)
     

  • Bitcoin CAD

    84,557.85
    +2,282.86 (+2.77%)
     

  • CMC Crypto 200

    1,283.80
    +34.68 (+2.78%)
     

  • GOLD FUTURES

    2,331.90
    +1.10 (+0.05%)
     

  • RUSSELL 2000

    2,022.35
    -8.47 (-0.42%)
     

  • 10-Yr Bond

    4.2380
    -0.0100 (-0.24%)
     

  • NASDAQ futures

    19,998.50
    +26.25 (+0.13%)
     

  • VOLATILITY

    12.84
    -0.49 (-3.68%)
     

  • FTSE

    8,247.79
    -33.76 (-0.41%)
     

  • NIKKEI 225

    39,400.77
    +227.62 (+0.58%)
     

  • CAD/EUR

    0.6833
    +0.0001 (+0.01%)
     

Third Harmonic Bio to Participate in the Jefferies Global Healthcare Conference

Third Harmonic Bio
·1 min read

SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chief Executive Officer, Natalie Holles, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 7:30 a.m. ET.

A live audio webcast will be available within the Investors & Media section of the Third Harmonic Bio website. An archived replay will be accessible for 90 days following the event.

About Third Harmonic Bio, Inc.
Third Harmonic Bio is a clinical stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases through the development of novel, highly selective, small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Early clinical studies demonstrate that KIT inhibition has the potential to revolutionize the treatment of a broad range of mast-cell-mediated inflammatory diseases, and that a titratable, oral small molecule inhibitor may provide the optimal therapeutic profile against this target. Third Harmonic Bio’s lead product candidate, THB335, is a titratable, oral, small molecule inhibitor that is currently in a Phase 1 clinical trial. For more information, please visit the Third Harmonic Bio website: www.thirdharmonicbio.com.

Investor and Media Contact:
Lori Murray
lori.murray@thirdharmonicbio.com